富士フイルムホールディングス(株)【4901】の掲示板 2021/01/27〜2021/01/30

>>1155

Shares of Dr. Reddy’s Laboratories Ltd. RDY fell 4.13% after it announced the termination of the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting. The study is being conducted in partnership with Global Response Aid FZCO (GRA). However, shares of Dr. Reddy’s have soared 48.2% in the past yearcompared with the industry’s growth of 11.9%.

The data from the Kuwait CVD-04-CD-001 study involving moderate-severe COVID-19 hospitalized patients did not show a statistically significant difference for the primary endpoint (i.e. time to sustained hypoxia resolution) for Aviganversus Placebo.『 The subgroup analysis of the low-risk study cohort (n=181) showed a 3-day earlier discharge in the Avigan group compared to the placebo group. 』The subgroup analysis data during the initial interim analysis showed that an antiviral drug,Avigan, may be effective as part of early treatment initiation in COVID-19 patients and not effective in the late-stage hospital treatment for moderate and severe COVID-19 patients. The full data analysis on 353 subjects would be available by the end of February 2021.

『』の部分を見て下さい。
軽症者ではアビガングループがプラセボグループより3日早く退院したとあります。